Pinealon Side Effects: What the Studies Actually Measured
REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn
Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy
Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-10
Pinealon side effects have never been measured as the phrase implies. The tripeptide Glu-Asp-Arg has a human literature — Russian, open-label, no placebo, no adverse-event table. What it did record is more useful than a clean bill of health: the one study that tracked laboratory markers, in 32 patients, found a prooxidant signal and a fall in CD34+ blood cells. This page reports what was measured, what wasn’t, and where the animal and cell data fit.
Quick Answer: What the Pinealon Side-Effect Data Actually Shows
No adverse-event rate for Pinealon has ever been published. The human studies — 32 polymorbidity patients, an occupational study of lorry-drivers, a two-week study of locomotive-brigade workers — were open-label and measured biological-age and psychoemotional endpoints, not side effects (PMID 26390612, PMID 23734521, PMID 22708445). The one that tracked laboratory markers found prooxidant activity on chemiluminescence and a decrease in CD34+ hematopoietic cells read as “significant inhibition of hemopoiesis.” No placebo group anywhere. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.
The most complete “user experience” of Pinealon belongs to the 32 people (18 men, 12 women) aged 41-83 who took it, with the sister peptide Vesugen, in the polymorbidity study (PMID 26390612). The abstract’s arc: a “significant anabolic effect,” improved central-nervous-system activity, and biological-age indicators read as slowed aging — Vesugen doing more of the visible work.
How tolerable did they find it? Nobody published that. The study did publish prooxidant activity on chemiluminescence and a fall in CD34+ blood cells read as inhibited hemopoiesis. Elsewhere, an unstated number of 150 lorry-drivers, and locomotive-brigade workers on capsules for two weeks, improved on psychoemotional and adaptation indices (PMID 23734521, PMID 22708445) — no adverse-event column.
What that came with: a diagnosis, a defined preparation, laboratory measurement — none of which ships with a research vial — and no placebo arm.
Compiled from the published studies (PMID 26390612, PMID 23734521, PMID 22708445) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Looking for Lab-Tested Peptides?
Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.
Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.
In This Guide
- What Is Pinealon?
- How It’s Thought to Work
- The Human Studies
- The Missing Adverse-Event Column
- The Prooxidant and CD34+ Findings
- Route of Administration
- Beyond the Brain
- What Users Report: Self-Reported Effects From Reddit
- Timeline
- Long-Term Safety
- Who Was Studied
- Managing Side Effects
- What Was Administered
- Pinealon Alone vs With Vesugen
- Pinealon vs Its Peers
- The Research-Vial Reality
- Sourcing and Verification
- US Regulatory Status
- Frequently Asked Questions
- Glossary of Terms
What Is Pinealon?
Pinealon is the trade name for the synthetic tripeptide Glu-Asp-Arg — EDR in the mechanism literature — from the Saint Petersburg Institute of Bioregulation and Gerontology, the laboratory behind Epitalon, Cortexin, and Vesugen (PMID 21978084, PMID 33396470). In Russian usage it is a “cytogen”: a short peptide meant to normalize one target tissue, here the brain. Its claims — neuroprotection, hypoxia resistance, slowed “biological age” (PMID 18546825, PMID 22708445) — put it in anti-aging peptide discussions and research listings. The one human study that specifies its form used a capsule. It is not an approved drug in the United States.
How It’s Thought to Work
Two layers; the second matters for safety. In cerebellar granule cells, neutrophils, and PC12 cells, Pinealon restricted reactive-oxygen-species accumulation dose-dependently and reduced necrotic cell death (PMID 21978084). But the same paper found the antioxidant effect saturated at lower concentrations while cell-cycle modulation continued at higher ones — Pinealon “is able to interact directly with the cell genome.” The 2020 EDR review: the peptide is assumed to enter cells, bind histone proteins and/or RNA, and shift MAPK/ERK signaling, caspase-3, p53, SOD2, GPX1, PPARA, PPARG, serotonin, and calmodulin (PMID 33396470).
KEY TAKEAWAY
Marketed as an antioxidant; described by its developers as a chromatin-binding, gene-expression-changing compound. The only human check is one chromatin measurement its authors said “should be studied in future.”
The Human Studies
Three primary human studies, all Russian, none placebo-controlled. Polymorbidity: 32 people (18 men, 12 women) aged 41-83 with organic brain syndrome in remission received Pinealon and Vesugen; endpoints were biological-age indicators, chemiluminescence, CD34+ counts, and chromatin condensation (PMID 26390612). Lorry-drivers: 150 male lorry-drivers (mean age 43.3 +/- 0.9) and 150 male metal craftsmen (mean age 42.8 +/- 0.9) were screened for neurotic states; bioregulating peptides then improved psychoemotional indices and cut occupational risk of borderline mental disorders (p < 0.001-0.05), best with Pinealon plus Vesugen (PMID 23734521). The craftsmen were a prevalence comparison, not a placebo arm; how many drivers received peptides is unstated. Locomotive brigades: capsules for two weeks, improved biological-age parameters; no participant count, control group, or adverse-event reporting (PMID 22708445). None is a study of side effects.
The Missing Adverse-Event Column
There is no adverse-event rate for Pinealon anywhere in the literature — no headache percentage, no nausea count, no discontinuation figure, no placebo column. A side-effect profile needs humans, a control group, systematic recording, and publication; Pinealon has the first and, generously, the last (our eloralintide page shows the full set). When a listing says “no reported side effects,” read it literally: nobody set up a mechanism to report any. Absence of surveillance is not surveillance returning clean.
PERSONAL OBSERVATION — PI EDITORIAL
Reading these abstracts side by side, what struck us was where the candor appeared: the polymorbidity authors recommend Pinealon in the same paragraph where they report it behaved as a prooxidant and suppressed blood-cell precursors. Listings quote the 2011 cell paper’s “suppression of free radical levels” and never the 2015 human paper’s “prooxidant activity.”
The Prooxidant and CD34+ Findings
What the 32-person study recorded, in the authors’ words (PMID 26390612). First: “we’ve found the prooxidant activity through chemiluminescence” — enough that the authors reclassified both peptides as geroprotectors of “anabolic neuroprotective and no antioxidant type.” Second: a “decrease of markers CD34+ positive hematopoietic polypotent cells in blood has shown significant inhibition of hemopoiesis” — fewer circulating blood-forming stem cells. Third, a non-finding: chromatin condensation was unchanged, so the peptides are “safe on nuclear genetic level” — qualified at once with “this property should be studied in future.” Missing: the size of the CD34+ fall, whether it belonged to Pinealon, Vesugen, or both, whether it reversed, and any clinical consequence. A fourth thread from rats: dosed before carotid-artery occlusion, caspase-3 activity “moderately raises” (PMID 21809624), while the 2020 review lists caspase-3 among proteins EDR is supposed to reduce (PMID 33396470). Opposite directions; we report both.
Route of Administration
The only route a human study specifies is oral: “1 capsule containing 100 mkg of Pinealon 2 times a day” for two weeks — “mkg” being the abstract’s transliteration of micrograms (PMID 22708445). The research market sells lyophilized powder for reconstitution, implying injection or nasal use that no human study employed. An oral tripeptide meets digestive peptidases; an injected one does not. No injection studies exist, so no injection-site data exist.
PRACTICAL NOTES — STANDARD RESEARCH-VIAL HANDLING
- Sterile single-use technique is standard for any lyophilized peptide
- Oral data does not transfer to an injected or intranasal product
- Our bacteriostatic water guide covers reconstitution
Beyond the Brain
Pinealon is sold as a brain peptide, but the studies logged effects outside it: a “significant anabolic effect” and improved activity of unnamed “other vital organs” (PMID 26390612); restored “adaptive potential” and resistance to work stress in lorry-drivers with asthenic, anxious, depressive, and hysterical symptoms (PMID 23734521; see our cortisol and stress peptides guide). Animal behavior is more ambiguous: old rats dosed before carotid occlusion showed more “behavioral dream” — the abstract’s term for sleep-like behavior — while position-finding, motivational behavior, and motor performance all fell (PMID 21809624). Survival improved; activity dropped. On sleep, the better-studied comparison is our DSIP page and, for the trial-by-trial record, emideltide (DSIP) for sleep.
What Users Report: Self-Reported Effects From Reddit
The Russian studies above measured biological-age markers and questionnaires, not adverse events, so the only descriptions of what Pinealon does to a person day to day come from self-reports. We searched Reddit on September 4, 2026, found 88 relevant posts from 2023 to 2026 (a 2026 podcast mention drove a fresh wave), and read the comment threads of six, across r/Peptides, r/PeptideDiscussion, r/Biohackers, r/PeptideForum and r/Peptidesource. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. One structural problem colors the whole record: Pinealon is very often taken alongside Epitalon, and most posters cannot say which peptide did what.
The most serious reports are circadian, and they persisted. A poster who took 1 mg of Epitalon and 1 mg of Pinealon daily for two weeks on a “peptide specialist’s” advice, hoping to shift sleep earlier, began waking up to four hours early every day while still not getting sleepy until 1:30 a.m., described being bed-bound from the lack of sleep, and five months later was still waking too early most days (r/PeptideDiscussion). A second poster took 1 mg of Pinealon for ten days plus N-acetyl Epitalon for twenty in March 2024, found evening dosing made sleep worse and switched to mornings, watched sleep quality deteriorate during the course, and reported severe insomnia that set in two months later and was still present a year on; he acknowledged he had recently stopped fifteen years of near-daily cannabis, which muddies the attribution (r/Peptides). Two commenters in that thread said Epitalon alone had given them insomnia. Neither poster can separate the two peptides, and neither can rule out coincidence; both describe the same direction of effect.
A distinctive sensory report recurs: a warm, buzzing pressure in the head. The author of a 20 mg-cycle write-up, escalating from 1 to 2 mg a day in the mornings, described a non-painful, heat-like pressure after dosing with no headache, along with more interrupted sleep (a brain “far more active” at night, though onset and duration were unchanged) and a slight appetite increase while also on tirzepatide (r/PeptideForum). A commenter in the same thread independently described a buzz like pressure on the brain, followed the next day by a clean, calm feeling. In a separate thread a user four months in and titrated to 6 mg named anhedonia and reduced sexual interest as his main side effects (r/Biohackers). Evening dosing delaying sleep onset by hours came up again in a 2026 thread, where the same user found morning dosing fine (r/Peptidesource).
Wearable data cuts both ways. The most-upvoted Pinealon post of 2026 is a Garmin analysis from a user on 0.5 mg Epitalon plus 1 mg Pinealon: over two weeks his average sleep score rose from about 70 to 84, resting heart rate fell from 72 to 64 and HRV rose from 24 to 34 against a year of baseline, and he later suspected Pinealon was driving the REM gains (thread). In the same subreddit a man in his forties ran four evening injections escalating from 1 to 3 mg and saw no consistent change in sleep score, REM or next-day cognition, calling the variation random (thread). The top reply to that null result was a user whose sleep score jumped from the 60s to the 80s on the first of ten nightly 2 mg doses and stayed there after stopping. Several others reported very vivid dreams and REM rising to nearly a third of sleep; at least three said they felt nothing at all.
Doses in the wild bear no relation to the studies. The Russian workers’ study administered 100 mcg capsules twice a day; Reddit posters describe 1 to 6 mg injections, sometimes nightly, and argue about whether the peptide belongs in the morning (one insisted it raises serotonin and is inherently anti-sleep, offering no evidence) or at bedtime.
HOW TO READ SELF-REPORTS
Two people describe months of circadian disruption after a two-week course; one describes a factory reset of his sleep; several describe nothing. Every one of the serious reports involved Epitalon as well, at daily doses five to thirty times what the published workers’ study used. The pattern is consistent with a peptide that acts on sleep timing in some people and inert in others, and equally consistent with expectation, coincidence and two peptides being blamed for each other.
Timeline
No published data supports a week-by-week Pinealon side-effect calendar; any you find is invented. The only stated exposure window is two weeks (PMID 22708445); the polymorbidity abstract gives no duration, so the onset and persistence of its prooxidant and CD34+ findings are unknown. The one kinetic statement in the file is cellular — “a delayed time course of ERK 1/2 activation” (PMID 21978084) — not a timeline for a person.
Long-Term Safety
Pinealon is marketed for aging, which implies chronic use, and the longest exposure any human abstract states is two weeks (PMID 22708445). The polymorbidity authors flagged the hematopoietic and chromatin questions for future study (PMID 26390612); the 2020 review cites mechanism work, not a human follow-up (PMID 33396470). No multi-month human safety data exists — not because it came back reassuring, but because it was never collected.
Who Was Studied
Pinealon’s study populations are narrow: 32 patients aged 41-83 with polymorbidity and organic brain syndrome of “vascular and/or traumatic genesis” (PMID 26390612); male lorry-drivers averaging 43.3 years (PMID 23734521); locomotive-brigade workers of unstated age and number (PMID 22708445). Never studied in humans: healthy younger adults, anyone with a blood disorder — a real gap given the CD34+ finding — and pregnancy, where the only data is rats dosed during methionine-loaded pregnancy (PMID 22567179). The typical research buyer is in none of them.
Managing Side Effects
Nothing conventional. No Pinealon study reports adverse events, so none describes managing them — no dose reduction, no co-medication, no stopping rule. What the polymorbidity investigators did was measure: chemiluminescence, CD34+ counts, chromatin condensation (PMID 26390612). For a compound whose only signals are laboratory values, measurement is the whole toolkit, and no research buyer replicates it at home.
What Was Administered
One human dose exists in print: “1 capsule containing 100 mkg of Pinealon 2 times a day” for two weeks (PMID 22708445). The other human abstracts state no dose, and no human study links any dose to any side effect. The one dose-response curve is cellular: ROS restriction and cell death saturated at lower concentrations while cell-cycle modulation kept climbing (PMID 21978084). More Pinealon bought more genomic activity, not more antioxidant effect — the developers’ finding, not guidance.
DID YOU KNOW
The one published human dose is in micrograms, by mouth (PMID 22708445). Research-market vials are labeled in milligrams. No published human study connects the two.
Pinealon Alone vs With Vesugen
Unusually, the combination data is stronger than the monotherapy data: the polymorbidity study gave Pinealon and Vesugen (spelled “vezugen” in one abstract), and the lorry-driver study found the “best effect” from the two combined (PMID 26390612, PMID 23734521). No abstract separates the safety signals by peptide. Forum stacks — with Semax, with Epitalon, with the same laboratory’s cartilage tripeptide on our Cartalax side effects page — have no published human data. More on our brain-health peptides guide.
Pinealon vs Its Peers
Every comparison is cross-study or animal; different models and endpoints are the caveat. Against Cortexin in 18-month rats, Cortexin showed “a more pronounced effect on free radical processes and caspase 3 activity”; both promoted adrenergic-mediator accumulation under hypoxia and cortical serotonin under hypothermia (PMID 28509493). Against Vilon, Epitalon, and Vesugen in hypobaric hypoxia, Pinealon was “the most pronounced” antihypoxic (PMID 18546825) — Epitalon being a different peptide from the same laboratory. A 2013 review files Pinealon with Semax and Kortagen as short peptides, against the polypeptide complexes Cortexin and Cerebrolysin (PMID 24738258). Semax’s deeper literature is why its analogue gets its own Adamax side effects page; for anxiety claims, see our anxiety peptides guide.
The Research-Vial Reality
Everything above describes a Russian capsule preparation given to selected patients with laboratory follow-up. A lyophilized vial from a research storefront shares a sequence name with that and nothing else verifiable without testing. The gap shows up three ways: identity and purity (a batch-matched COA is the only evidence the vial holds Glu-Asp-Arg at the stated quantity — see our COA reading guide), concentration arithmetic (our peptide calculator does the math), and no laboratory monitoring — the ingredient that produced this compound’s only safety signals. Compounds in this channel are sold strictly for non-human research use.
Sourcing and Verification
Pinealon is an old compound in a young market: the cell paper is from 2011, the human studies from 2012 to 2015, and Western listings are newer than both. The checklist: batch-matched COA, independent third-party testing with a verifiable report number, and skepticism toward any listing quoting “biological age” from a two-week occupational study. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like; our guide library covers verification.
US Regulatory Status
Pinealon is not FDA-approved for any use and circulates here solely as research-market material sold for non-human research use (see our research-chemical regulation guide). The most concrete recent regulatory document: Medsafe, June 2025 reported 56 peptide or SARM parcels intercepted between 1 April 2025 and 19 May 2025, and recommended that “pineal gland peptides and their analogues, both naturally occurring and synthetically derived” be classified as prescription medicines as a group — a class that “would capture any new/novel products with a similar mode of action and/or chemical structure.” It names Epitalon and Epithalamin. The document does not name Pinealon. Whether a synthetic tripeptide with the pineal gland in its trade name falls inside that class is the regulator’s call.
PERSONAL OBSERVATION — PI EDITORIAL
In listings we’ve reviewed, Pinealon is sold on two phrases: “suppression of free radical levels,” from the 2011 cell paper’s title, and “biological age,” from the occupational studies. The 2015 human paper that found prooxidant activity and inhibited hemopoiesis never makes the product page. When a vendor cites a literature, read the paper the vendor skipped.
Frequently Asked Questions
What are the most common Pinealon side effects?
No rate has ever been published; no Pinealon study recorded adverse events against a control group. The only safety-relevant findings, from a 32-person Russian study, are prooxidant activity and a CD34+ decrease read as “significant inhibition of hemopoiesis.”
Is Pinealon safe?
Unanswered. The human studies were open-label, without placebo, and did not report adverse events; the one that measured laboratory markers found two signals against the compound. Nothing documents harm in a person; nothing demonstrates safety.
Did any Pinealon study use a placebo?
No. The polymorbidity study reports no control arm, the lorry-driver study compared drivers to metal craftsmen for prevalence of neurotic states, and the locomotive-brigade study reports no control group.
Does Pinealon suppress blood-cell production?
One study says the marker moved that way: CD34+ hematopoietic cells decreased in blood, read as inhibited hemopoiesis. No magnitude, no separation from the co-administered Vesugen, and no clinical consequence were reported.
Is Pinealon an antioxidant or a prooxidant?
Both, by setting. In cultured cells it restricted reactive oxygen species dose-dependently; in the 32-person human study it showed prooxidant activity, and the authors reclassified it as a geroprotector of “no antioxidant type.”
Is Pinealon regulated anywhere?
Not FDA-approved; sold in the US only for non-human research use. In June 2025, New Zealand’s Medsafe recommended classifying pineal-gland peptides and their synthetic analogues as prescription medicines; it names Epitalon and Epithalamin, not Pinealon.
Glossary of Terms
- Cytogen (bioregulator): Russian term for a short synthetic peptide meant to normalize one target tissue.
- EDR: Pinealon’s one-letter sequence — glutamic acid (E), aspartic acid (D), arginine (R).
- Prooxidant activity: a net increase in oxidative signal rather than a decrease; seen in the polymorbidity study by chemiluminescence.
- Chemiluminescence: a laboratory method measuring light emitted by oxidative reactions — a readout of free-radical activity.
- CD34+ cells: hematopoietic stem and progenitor cells carrying the CD34 marker; their decrease was read as inhibited blood-cell formation.
- Open-label: a study with no blinding and no placebo comparison — the design of every human Pinealon study.
- COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.
References
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes — Rejuvenation Res, 2011 (PubMed)
- Pinealon protects the rat offspring from prenatal hyperhomocysteinemia — Int J Clin Exp Med, 2012 (PubMed)
- Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission — Adv Gerontol, 2015 (PubMed)
- The peptide correction of neurotic disorders among professional truck-drivers — Adv Gerontol, 2012 (PubMed)
- Neuroprotective effects of peptides bioregulators in people of various age — Adv Gerontol, 2013 (PubMed)
- Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades — Adv Gerontol, 2012 (PubMed)
- Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia — Adv Gerontol, 2015 (PubMed)
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease — Molecules, 2020 (PubMed)
- Investigation of antihypoxic properties of short peptides — Adv Gerontol, 2008 (PubMed)
- Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats — Adv Gerontol, 2011 (PubMed)
- Classification of Unscheduled Peptides — Medsafe (NZ), June 2025